A5071088060- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- Nausea and vomiting management
- Healthcare cost, quality, practices
- Health and Medical Research Impacts
- Nosocomial Infections in ICU
- Cervical Cancer and HPV Research
- Pharmaceutical studies and practices
- Liver Disease Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Prenatal Screening and Diagnostics
- Anesthesia and Pain Management
- Alzheimer's disease research and treatments
- Emergency and Acute Care Studies
- HIV Research and Treatment
- HER2/EGFR in Cancer Research
- Biomedical Ethics and Regulation
- Organ Donation and Transplantation
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Organ Transplantation Techniques and Outcomes
Belgian Health Care Knowledge Centre
2014-2025
New York University Press
2020
Cambridge University Press
2020
Royal Australasian College of Surgeons
2020
The University of Adelaide
2020
Agencia de Evaluación de Tecnologías Sanitarias
2020
Fujirebio (Belgium)
1999-2006
Antwerp University Hospital
2004
Abbott (Canada)
2004
The Royal Free Hospital
2004
<b>Background and Aims:</b> Epidemiology studies have shown that cardiovascular (CV) disease is primarily responsible for the mortality associated with increased pulmonary environmental particle (PM<sub>10</sub>) exposure. The mechanisms involved in PM<sub>10</sub> mediated CV effects are unknown although changes plasma viscosity homoeostasis of blood coagulation been implicated. It was hypothesised exposure would result an inflammatory response enhance activation extrinsic vascular cells...
The emergence of the precision medicine paradigm in oncology has led to increasing interest integration real-world data (RWD) into cancer clinical research. As sources evidence (RWE), such could potentially help address uncertainties that surround adoption novel anticancer therapies clinic following their investigation trials. At present, RWE-generating studies which investigate antitumour interventions seem primarily focus on collecting and analysing observational RWD, typically forgoing...
To study the expression of activation markers human leukocyte antigen (HLA)-DR and CD38 on CD8+ T-lymphocytes in HIV-infected subjects HIV-negative controls.Two- three-colour flow-cytometric analysis.Fresh peripheral venous blood was obtained from 16 subjects, representing four different stages HIV disease, six controls. Three-colour lymphocyte immunophenotyping performed using peridinyl chlorophyll-A protein (PerCP)-conjugated anti-CD8 monoclonal antibody (MAb) combination with anti-HLA-DR...
The objective of this prospective cohort study was to evaluate the expression activation markers on CD8 lymphocytes at various clinical stages HIV infection and determine value these in identifying patients likely have rapidly progressive disease. One hundred three HIV+ patients, divided into four disease stages, 34 seronegative controls were evaluated entry using flow cytometric immunophenotyping. followed clinically for progression during following 2 years. cell numbers percentage are...
Abstract Clin Chem Lab Med 2006;44:1472–80.
Real world data are advocated as an alternative approach to RCTs for closing knowledge gaps on drugs, but <b>Beate Wieseler and colleagues</b> argue that this is the wrong remedy current challenges in drug development
ABSTRACT Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total 159 serum samples from 33 chronic patients receiving were analyzed at four centers for presence mutations codons 528 [180] (proposed revised nomenclature...
New treatments are needed for chronic hepatitis C patients in whom viral clearance cannot be achieved. Thirty–five (genotype 1) were randomized to receive 20 μg of recombinant HCV E1 (E1) (n = 26) or placebo 9) intramuscularly at weeks 0, 4, 8, 12, and 24. Thirty–four then received open–label vaccine 50, 53, 56, 59, 62, 65. Twenty–four (12 men, 12 women; mean age, 52 y; 18 interferon–based treatment failures; baseline alanine aminotransferase [ALT] level, 118 IU/L) underwent a biopsy before...
Background The first- and second-trimester screening for trisomy 21 (T21) are reimbursed all pregnant women in Belgium. Using a cut-off risk of 1:300 T21, about 5% referred definitive prenatal diagnosis using an invasive test, at sensitivity (only) 72.5%. specificity the non-invasive test (NIPT) over 99% but come cost €460 (£373) per test. objective is to estimate consequences introducing NIPT detection T21. Methods A cost-consequences analysis was performed presenting impact on benefits,...
Many of the 40 000 transcatheter procedures so far carried out cannot be justified on medical or cost effectiveness grounds. <b>Hans Van Brabandt</b>, <b>Mattias Neyt</b>, and <b>Frank Hulstaert </b>examine why practice has gone beyond evidence
Assessing the overall burden of disease which can be attributed to hospital-acquired infections (HAIs) remains a challenge. A matched cohort study was performed estimate excess mortality, length stay and costs attributable HAIs in Belgian acute-care hospitals, using six matching factors (hospital, diagnosis-related group, age, ward, Charlson score, estimated prior infection). Information combined from different sources on epidemiology impact at national level. The total number patients...
High-quality clinical evidence is most often lacking when novel high-risk devices enter the European market. At same time, a randomized controlled trial (RCT) initiated as requirement for obtaining market access in US. Should coverage Europe be postponed until RCT data are available? We studied premarket evaluation of innovative medical compared with US, and medicines, where appropriate.The literature regulatory documents were checked. Representatives from industry, Competent Authorities,...
Abstract Background Investigator-led multicentre randomised trials are essential to generate evidence on the optimal use of medical interventions. These non-commercial often hampered by underfunding, which may lead difficulties in gathering a team with necessary expertise, delayed trial start, slow recruitment and even early discontinuation. As new public funder pragmatic clinical trials, KCE Trials programme was committed correctly pay all activities order assure timely delivery...